Tenjarla Srini reported SER

Source

Document

SEC Form 4

Publisher

U.S. Securities and Exchange Commission (EDGAR)

Document ID

0002029985-26-000002

Machine-readable

Structured copy

Timestamps

Event (reported)

Feb 3, 2026

Published

Feb 17, 2026

Ingested by INSIDER

Nov 5, 04:16 UTC

Last re-read

Nov 5, 04:16 UTC

Extracted facts

Filer

Tenjarla Srini

Role

SVP, CMC & Formulation

Transaction

Grant or awardAs filed: “A”

Asset

Serina Therapeutics, Inc. — Stock Option (right to buy)

Ticker

SER

Shares

69.0K

Price per share

$0

Execution date (reported)

Feb 3, 2026

Owned after transaction

69.0K shares

Days from execution to publication

14

What this establishes

Tenjarla Srini filed this Form 4 reporting a grant or award of SER on Feb 3, 2026. It became public on Feb 17, 2026. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.

Extraction

Method

Form 4 XML

Confidence

1.00

SVP, CMC & Formulation

Tenjarla Srinicik:0002029985

Issuer

Serina Therapeutics, Inc.cik:0001708599

Revision history · 0

No field has changed since this record was first ingested.